Table 2.

The virologic responses in both groups.

Response	Fixed 12 weeks (Ref.)	Response-tailored (test)	Proportion difference (Ref-test)	Z	P (2-tail)
vRVR (ITT)	49/60 (81.67%) (CI: 70.08–89.44%)	48/60 (80%) (CI: 68.22–88.17%)	1.67%) (CI: − 12.51–+15.78%)	0.232	0.817
SVR12 (ITT)	58/60 (96.67%) (CI: 88.64–99%)	59/60 (98.33%) (CI: 91.14–99.71%)	(− 1.67%) (CI: − 9.8%–+5.9%)	0.6	0.569
SVR12 (PP)	58/59 (98.31%) (CI: 91–99.7%)	59/59 (100%) (CI: 93.89–100%)	(− 1.69%) (CI: − 9%–+4.58%)	1	0.315
SVR12/8w (ITT)		47/48 (97.92%) (CI: 89.1–99.6%)
SVR12/8w (PP)		47/47 (100%) (CI: 92.4–100%)

vRVR (very rapid virologic response at week 2).

SVR12 (sustained virologic response at 12 weeks post-treatment).

SVR12/8w (sustained virologic response at 12 weeks after the end of 8 weeks-treatment course).

Data are n/N (%) (95% Confidence Interval (CI:) by Wilson score method).

ITT (Intention-to-treat population); PP (Per Protocol analysis for those who completed the full protocol).